(68)Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy.
Authors : Shagera QA, Artigas C, Karfis I, Critchi G, Chanza NM, Sideris S, Peltier A, Paesmans M, Gil T, Flamen P Year : 2022 Journal : J Nucl Med
The role of PSMA radioligands in the diagnosis and treatment of prostate carcinoma.
Authors : Rodríguez-Fraile M, Tamayo Alonso P, Rosales JJ, de Arcocha-Torres M, Caresia-Aróztegui AP, Cózar-Santiago MP, Orcajo-Rincon J, Simó Perdigó M, Delgado Bolton RC, Artigas C Year : 2022 Journal : Rev Esp Med Nucl Imagen Mol (Engl Ed)
Lung uptake detected by 68Ga-PSMA-11 PET/CT in prostate cancer patients with SARS-CoV-2: a case series.
Authors : Farolfi A, Telo S, Castellucci P, Morais de Campos AL, Rosado-de-Castro PH, Altino de Almeida S, Artigas C, Scarlattei M, Leal A, Deandreis D, Fanti S, Fendler WP, Mosconi C, Pianori D, Ruffini L, Ceci F Year : 2021 Journal : Am J Nucl Med Mol Imaging
Targeted radionuclide therapy: an emerging field in solid tumours.
Authors : Artigas C, Mileva M, Flamen P, Karfis I Year : 2021 Journal : Curr Opin Oncol
Oligometastatic Disease Detection with <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact.
Authors : Artigas C, Diamand R, Shagera QA, Plouznikoff N, Fokoue F, Otte FX, Gil T, Peltier A, Van Gestel D, Flamen P Year : 2021 Journal : Cancers (Basel)